Dr. Bardia on Dual Targeting of the HER2 Receptor

Dr. Bardia Describes the Snapshot Assay for Breast CancerПодробнее

Dr. Aditya Bardia on RAD1901 in ER-Positive Metastatic Breast CancerПодробнее

Dr. Bardia on the Clinical Utility of Liquid Biopsies in Breast CancerПодробнее

Leveraging Targeted Therapies to Improve Outcomes Across the Continuum of HER2+ Breast CancerПодробнее

Role for Neratinib Following Adjuvant Dual-Targeted HER2 TherapyПодробнее

Dr. Gradishar Discusses Dual HER2-Targeting in Breast CancerПодробнее

The HER Pathway and CancerПодробнее

Dr Bardia on Current Approaches to HER2+ Breast Cancer ManagementПодробнее

Dr. Bardia Discusses Recent Advancements in the Field of Breast CancerПодробнее

Dr. Elias on Androgen Receptor Inhibitors in HER2-Positive Breast CancerПодробнее

Outcomes from ADAPT-HR-/HER2+ evaluating dual HER2 blockadeПодробнее

Drs. Bardia, Hurvitz, & Spring talk #BreastCancer during #ASCO22 - https://bit.ly/3tVN82XПодробнее

Treating ER+/HER2-low metastatic breast cancer, 2L and beyondПодробнее

State of the Art: Targeting Mutant ERПодробнее

Dr. Bhave on Promising Anti-HER2 Agents in HER2+ Breast CancerПодробнее

CALGB 40601 Alliance: impact of dual HER2 targeting on pCRПодробнее

New dual targeting approach for combating hormone receptor positive breast cancerПодробнее

Dr. Chang Discusses Combining HER2 Targeted TherapiesПодробнее

Molecular Interrogation of Circulating Tumor Cells for Drug Development in Breast CancerПодробнее